In ophthalmological clinical trials, sociodemographic disparities still exist.

Published Date: 01 Mar 2023

Ophthalmological Clinical Trials Still Show Sociodemographic Disparities.

Read Full News

Latest News

Sarcoid Uveitis: 1 in 3 Achieve Remission, Relapses Rare

Remission is achievable and relapses are uncommon in patients with sarcoid uveitis, although those with swelling in the macular region may experience delayed remission.

Female Eye Doctors Earn Less Across All Ranks

Women in academic ophthalmology earn less than men across all ranks, with a pay-gap over a full career of roughly $1 million, a study finds.

US FDA Declines to Approve Aldeyra's Eye Disorder Drug, Shares Slump

The U.S. Food and Drug Administration declined to approve Aldeyra Therapeutics' drug for a type ⁠of eye disease, the company said on Tuesday, sending its shares plunging...

Light Therapy May Improve Vision in Patients With Dry AMD

Light therapy with multiple wavelengths may safely improve vision, reduce new retinal damage, and improve vision related quality of life in patients with dry age related macular degeneration.

Spanish Researchers Develop Low-cost Artificial Cornea From Fish Scales

Researchers at Spain's University of Granada have developed an artificial cornea made from the scales ⁠of several fish species commonly found in markets, which could become...

Glaucoma Coaches Boost Med Adherence, Study Finds

Patients who went through the SEE program in Michigan were more likely to stick to their drug regimen and reported less distress related to their condition.

Todays Updates

Low Income, Education Tied to Depression in Older Adults

Older adults with chronic disease who have less education, lower income, and no active jobs tend to experience symptoms of depression.

Infection Burden High With Myeloma T-Cell Therapies

A retrospective study suggests a high burden of prolonged, mostly low-grade infections in patients with multiple myeloma who receive T-cell-engaging therapies.

Weight-Based and Fixed-Dose Pembrolizumab Compared in NSCLC

A national cohort study compares the safety and efficacy of weight-based and fixed-dose pembrolizumab regimens in patients with advanced non-small cell lung cancer.

HER2 ADC Shows Promise in Recurrent Endometrial Cancer

Trastuzumab pamirtecan, a HER2-targeted antibody-drug conjugate, achieved ‘exceptional’ antitumor responses in patients with recurrent endometrial cancer, especially those with HER2 IHC 3+ tumors.

Todays Updates

Low Income, Education Tied to Depression in Older Adults

Older adults with chronic disease who have less education, lower income, and no active jobs tend to experience symptoms of depression.

Infection Burden High With Myeloma T-Cell Therapies

A retrospective study suggests a high burden of prolonged, mostly low-grade infections in patients with multiple myeloma who receive T-cell-engaging therapies.

Weight-Based and Fixed-Dose Pembrolizumab Compared in NSCLC

A national cohort study compares the safety and efficacy of weight-based and fixed-dose pembrolizumab regimens in patients with advanced non-small cell lung cancer.

HER2 ADC Shows Promise in Recurrent Endometrial Cancer

Trastuzumab pamirtecan, a HER2-targeted antibody-drug conjugate, achieved ‘exceptional’ antitumor responses in patients with recurrent endometrial cancer, especially those with HER2 IHC 3+ tumors.

Latest News

Remission is achievable and relapses are uncommon in patients with sarcoid uveitis, although those with swelling in the macular region may experience delayed remission.

Women in academic ophthalmology earn less than men across all ranks, with a pay-gap over a full career of roughly $1 million, a study finds.

The U.S. Food and Drug Administration declined to approve Aldeyra Therapeutics' drug for a type ⁠of eye disease, the company said on Tuesday, sending its shares plunging...

Light therapy with multiple wavelengths may safely improve vision, reduce new retinal damage, and improve vision related quality of life in patients with dry age related macular degeneration.

Researchers at Spain's University of Granada have developed an artificial cornea made from the scales ⁠of several fish species commonly found in markets, which could become...

Patients who went through the SEE program in Michigan were more likely to stick to their drug regimen and reported less distress related to their condition.

News All Time

Two Biologics Show Comparable Benefit in Uveitis

Adalimumab and tocilizumab perform similarly in controlling inflammation while reducing the use of corticosteroids at week 16 in patients with refractory, noninfectious uveitis.

Ocular Therapeutix Plunges as Modest Benefit Overshadow Trial Win Over Regeneron's Eylea

Ocular Therapeutix's experimental eye drug showed superiority to Regeneron's Eylea in a key late-stage trial, but ⁠its modest advantage and higher rates of certain side...

Early Retinal Fluid Drying May Extend Injection Gaps in AMD

Rapid drying of retinal fluid with faricimab injections may help identify patients with neovascular age-related macular degeneration who can safely extend time between injections.

PDS Ranibizumab Retains Visual Acuity Gains in nAMD, with John Kitchens, MD John W. Kitchens, MD

The ongoing Archway-Portal extension study indicates the lasting efficacy and safety of ranibizumab dosing via the Port Delivery System.

FDA Approves First Dual-Agent Eye Drop for Near Vision Loss

FDA Approves First Dual-Agent Eye Drop for Near Vision Loss

FDA Approves Labeling Update for iDose TR for Open-Angle Glaucoma and Ocular Hypertension

FDA Approves Labeling Update for iDose TR for Open-Angle Glaucoma and Ocular Hypertension

The HCPFive: Top News for Healthcare Providers from the Week of 12/28

The HCPFive: Top News for Healthcare Providers from the Week of 12/28

FDA Issues Complete Response Letter for ONS-5010 for Wet AMD

FDA Issues Complete Response Letter for ONS-5010 for Wet AMD

Ophthalmology in 2025: Year in Review

Ophthalmology in 2025: Year in Review

FDA Accepts, Grants Priority Review to Veligrotug BLA for Thyroid Eye Disease

FDA Accepts, Grants Priority Review to Veligrotug BLA for Thyroid Eye Disease

FDA Extends PDUFA Date for Reproxalap in Dry Eye Disease to March 2026

FDA Extends PDUFA Date for Reproxalap in Dry Eye Disease to March 2026

6 Ophthalmology Headlines You Missed in October 2025

6 Ophthalmology Headlines You Missed in October 2025

New Parameters for Faster Geographic Atrophy Progression Established, with Srinivas Sadda, MD Srinivas Sadda, MD

The pooled sham cohorts of the OAKS and DERBY trials have revealed a series of indicators for faster geographic atrophy lesion growth.

OCU-410 Gene Therapy Preserves Visual Acuity and Slows GA Lesion Progression, with Jay Chhablani, MD Jay Chhablani, MD

Recent phase 1/2 trial data indicate the safety and efficacy of the surgical, subretinal injection in monitoring cellular homeostasis.

Intravitreal UBX1325 Shows Efficacy in Diabetic Retinopathy, DME, with Dante Pieramici, MD Dante J. Pieramici, MD

Results from the BEHOLD and ASPIRE trials indicate the long lasting effects of UBX1325 in improving retinal function and structure.

Psoriasis Associated with Risk of Age-Related Macular Degeneration Ryan Livingston

Based on 3 propensity-matched control groups, patients with psoriasis can have anywhere from a 40% to 56% higher risk.

Recommended News For You

In Sickle Cell Disease, Lovo-Cel is "Life-Changing, Transformative.".

New BiTE Agent for Small Cell Lung Cancer Approved by the FDA.

The standard for high-risk prostate cancer is supported by a study using high-dose RT and long-term ADT.

According to a study, breast cancer in Syrian refugees tends to be diagnosed at an earlier stage and with more advanced tumors.

What Comes After Cancer?

EBV Screening Tied to Lower Nasopharyngeal Cancer Mortality Risk

Colon cancer and exercise: Can physical activity reprogram genes?

Recommended Articles For You

Does Lactate Signal Anemia? Exploring the Complexities of Hyperlactatemia and Red Blood Cell Health 

Recent Advances in Paroxysmal Nocturnal Hemoglobinuria Research: Promising Therapies on the Horizon  

Unlocking the Secrets of Improved Ovarian Cancer Survival Rates 

The Unseen Threat: Uncovering the Risks of Pancoast Tumor 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Recurrent UTIs impact eGFR in children with vesicoureteral reflux

2.

Inner Thoughts of Leonard Bernstein, the "Maestro".

3.

The need for more Latinx participants in Alzheimer's trials is urgent.

4.

Potentially Novel Approach for Treating Advanced Colorectal Cancer with KRAS Mutations.

5.

BlurryScope: A compact, AI-powered microscope for rapid, cost-effective cancer scoring

1.

Evolving Cancer Treatments: Innovations, Success Rates, and Mechanisms

2.

Mechanistic Depth and Clinical Impact of Rusfertide, Onyvide, IV Avastin, and Pemfexy

3.

Refractory Iron Deficiency Anemia in a Young Adult: Diagnostic Challenges

4.

The Complications and Treatments of Intraosseous Hemangioma - A Comprehensive Guide

5.

Understanding Evans Syndrome: Causes, Symptoms, and Treatment Options 

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part III

2.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part IV

3.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VIII

4.

Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in MRD Negativity

5.

Current Scenario of Blood Cancer- Genomic Testing & Advancement in Diagnosis and Treatment


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot